Generic Medicine Info
Indications and Dosage
Androgen deficiency, Infertility due to hypogonadism
Adult: Initially, 75-100 mg daily in 3-4 divided doses for several months. Maintenance: 50-75 mg daily. Treatment recommendations may vary between countries (refer to specific product guidelines).
May be taken with or without food.
Prostatic carcinoma, current or history of liver tumours.
Special Precautions
Patient with a history of MI or CAD; conditions influenced by oedema (e.g. CV disease, seizure, migraine), polycythaemia. Not indicated for use in women. Not indicated for enhancing muscular development or physical ability in healthy individuals. Renal and hepatic impairment.
Adverse Reactions
Significant: Frequent or persistent erections, excessive sexual stimulation; increased risk of prostate cancer; VTE.
Potentially Fatal: Rarely, benign or malignant liver tumours, intra-abdominal haemorrhage.
Monitoring Parameters
Monitor lipid profile. Perform prostate examination prior to starting therapy and routinely during therapy.
Lab Interference
May interfere with thyroid function test and glucose tolerance test.
Mechanism of Action: Mesterolone is an orally active androgen with less inhibitory effect on intrinsic testicular function than testosterone. It stimulates receptors in tissues and organs to promote the growth and development of male sex organs and to maintain secondary sex characteristics in androgen-deficient males.
Absorption: Rapidly and almost completely absorbed. Bioavailability: 3%. Time to peak plasma concentration: 1.6 ± 0.6 hours.
Distribution: Plasma protein binding: 98% (40% to albumin and 58% to sex hormone binding globulin).
Metabolism: Rapidly metabolised in the liver into metabolites including 1α-methylandrosterone and 1α-methyl-5α-androstane-3α, 17β-diol.
Excretion: Via urine (80% as metabolites); faeces (13% as metabolites). Elimination half-life: 12-13 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 15020, Mesterolone. Accessed Feb. 23, 2023.

Store below 30°C.
MIMS Class
Androgens & Related Synthetic Drugs
ATC Classification
G03BB01 - mesterolone ; Belongs to the class of 5-androstanon (3) derivative androgens used in androgenic hormone preparations.
Anon. Mesterolone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 16/11/2022.

Buckingham R (ed). Mesterolone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 16/11/2022.

Pro-viron (Bayer PLC). MHRA. Accessed 16/11/2022.

Disclaimer: This information is independently developed by MIMS based on Mesterolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Malvinum
  • Provironum
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in